{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:55:59Z","timestamp":1794855359977,"version":"4.9.1"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer (OC) is the most lethal gynecological malignancy due to tumor heterogeneity, the lack of reliable early diagnosis methods and the high incidence of chemoresistant recurrent disease. Although there are developments in chemotherapies and surgical techniques to improve the overall survival of OC patients, the 5-year survival of advanced OC patients is still low. To improve the prognosis of OC patients, it is important to search for novel therapeutic approaches. Cancer stem cells (CSCs) are a subpopulation of tumor cells that participate in tumor growth, metastasis and chemoresistance. It is important to study the role of CSCs in a highly heterogeneous disease such as OC, which may be significant to a better understanding of the oncogenetic and metastatic pathways of the disease and to develop novel strategies against its progression and platinum resistance. Here, we summarized the current findings about targeting methods against ovarian cancer stem cells, including related signaling pathways, markers and drugs, to better manage OC patients using CSC-based therapeutic strategies.<\/jats:p>","DOI":"10.1186\/s13287-023-03244-4","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T05:04:16Z","timestamp":1676351056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Targeting ovarian cancer stem cells: a new way out"],"prefix":"10.1186","volume":"14","author":[{"given":"Huiying","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7975-3296","authenticated-orcid":false,"given":"Zhumei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"issue":"1","key":"3244_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"key":"3244_CR2","volume-title":"WHO classification of tumours of the female reproductive organs","author":"RJ Kurman","year":"2014","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of the female reproductive organs. Lyon: WHO Press; 2014."},{"issue":"5","key":"3244_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/PAP.0000000000000243","volume":"26","author":"Y Hatano","year":"2019","unstructured":"Hatano Y, Hatano K, Tamada M, Morishige KI, Tomita H, Yanai H, Hara A. A comprehensive review of ovarian serous carcinoma. Adv Anat Pathol. 2019;26(5):329\u201339. https:\/\/doi.org\/10.1097\/PAP.0000000000000243.","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"3244_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","volume":"186","author":"RJ Kurman","year":"2016","unstructured":"Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733\u201347. https:\/\/doi.org\/10.1016\/j.ajpath.2015.11.011.","journal-title":"Am J Pathol"},{"issue":"1","key":"3244_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-9966-31-14","volume":"31","author":"A Kim","year":"2012","unstructured":"Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31(1):14. https:\/\/doi.org\/10.1186\/1756-9966-31-14.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3244_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2017.03.515","volume":"146","author":"MK Siddiqui","year":"2017","unstructured":"Siddiqui MK, Tyczynski J, Pahwa A, Fernandes AW. Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer. Gynecol Oncol. 2017;146(1):44\u201351. https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.515.","journal-title":"Gynecol Oncol"},{"key":"3244_CR7","doi-asserted-by":"publisher","first-page":"754524","DOI":"10.3389\/fonc.2021.754524","volume":"11","author":"RC Bonadio","year":"2021","unstructured":"Bonadio RC, Estevez-Diz MDP. Perspectives on PARP inhibitor combinations for ovarian cancer. Front Oncol. 2021;11:754524. https:\/\/doi.org\/10.3389\/fonc.2021.754524.","journal-title":"Front Oncol"},{"key":"3244_CR8","doi-asserted-by":"publisher","first-page":"743073","DOI":"10.3389\/fphar.2021.743073","volume":"12","author":"Q Xu","year":"2021","unstructured":"Xu Q, Li Z. Update on poly ADP-ribose polymerase inhibitors in ovarian cancer with non-BRCA mutations. Front Pharmacol. 2021;12:743073. https:\/\/doi.org\/10.3389\/fphar.2021.743073.","journal-title":"Front Pharmacol"},{"key":"3244_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","volume":"73","author":"E Franzese","year":"2019","unstructured":"Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, De Vita F, Pignata S, Ciardiello F, Orditura M. PARP inhibitors in ovarian cancer. Cancer Treat Rev. 2019;73:1\u20139. https:\/\/doi.org\/10.1016\/j.ctrv.2018.12.002.","journal-title":"Cancer Treat Rev"},{"key":"3244_CR10","doi-asserted-by":"publisher","first-page":"577869","DOI":"10.3389\/fimmu.2020.577869","volume":"11","author":"C Yang","year":"2020","unstructured":"Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol. 2020;11:577869. https:\/\/doi.org\/10.3389\/fimmu.2020.577869.","journal-title":"Front Immunol"},{"issue":"Suppl 2","key":"3244_CR11","doi-asserted-by":"publisher","first-page":"s16","DOI":"10.1136\/ijgc-2019-000456","volume":"29","author":"D Zamarin","year":"2019","unstructured":"Zamarin D. Novel therapeutics: response and resistance in ovarian cancer. Int J Gynecol Cancer. 2019;29(Suppl 2):s16\u201321. https:\/\/doi.org\/10.1136\/ijgc-2019-000456.","journal-title":"Int J Gynecol Cancer"},{"issue":"1\u20132","key":"3244_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000479006","volume":"85","author":"M Kossa\u00ef","year":"2018","unstructured":"Kossa\u00ef M, Leary A, Scoazec JY, Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology. 2018;85(1\u20132):41\u20139. https:\/\/doi.org\/10.1159\/000479006.","journal-title":"Pathobiology"},{"key":"3244_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3389\/fonc.2020.00319","volume":"10","author":"N Terraneo","year":"2020","unstructured":"Terraneo N, Jacob F, Dubrovska A, Gr\u00fcnberg J. Novel therapeutic strategies for ovarian cancer stem cells. Front Oncol. 2020;10:319. https:\/\/doi.org\/10.3389\/fonc.2020.00319.","journal-title":"Front Oncol"},{"issue":"12","key":"3244_CR14","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra061808","volume":"355","author":"CT Jordan","year":"2006","unstructured":"Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355(12):1253\u201361. https:\/\/doi.org\/10.1056\/NEJMra061808.","journal-title":"N Engl J Med"},{"issue":"7","key":"3244_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730\u20137. https:\/\/doi.org\/10.1038\/nm0797-730.","journal-title":"Nat Med"},{"key":"3244_CR16","doi-asserted-by":"publisher","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983\u20138. https:\/\/doi.org\/10.1073\/pnas.0530291100. Erratum in: Proc Natl Acad Sci U S A. 2003;100(11):6890.","DOI":"10.1073\/pnas.0530291100"},{"issue":"7015","key":"3244_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396\u2013401. https:\/\/doi.org\/10.1038\/nature03128.","journal-title":"Nature"},{"issue":"9","key":"3244_CR18","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.ejca.2006.01.037","volume":"42","author":"AT Collins","year":"2006","unstructured":"Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer. 2006;42(9):1213\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2006.01.037.","journal-title":"Eur J Cancer"},{"issue":"7123","key":"3244_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature05384","volume":"445","author":"L Ricci-Vitiani","year":"2007","unstructured":"Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111\u20135. https:\/\/doi.org\/10.1038\/nature05384.","journal-title":"Nature"},{"issue":"8","key":"3244_CR20","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","volume":"65","author":"SA Bapat","year":"2005","unstructured":"Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005;65(8):3025\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3931.","journal-title":"Cancer Res"},{"issue":"11","key":"3244_CR21","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","volume":"68","author":"S Zhang","year":"2008","unstructured":"Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68(11):4311\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0364.","journal-title":"Cancer Res"},{"issue":"18","key":"3244_CR22","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/onc.2010.35","volume":"29","author":"MQ Gao","year":"2010","unstructured":"Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010;29(18):2672\u201380. https:\/\/doi.org\/10.1038\/onc.2010.35.","journal-title":"Oncogene"},{"issue":"12","key":"3244_CR23","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1002\/stem.236","volume":"27","author":"MD Curley","year":"2009","unstructured":"Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27(12):2875\u201383. https:\/\/doi.org\/10.1002\/stem.236.","journal-title":"Stem Cells"},{"issue":"19","key":"3244_CR24","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-10-2743","volume":"17","author":"H Korkaya","year":"2011","unstructured":"Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer\u2019s inflammatory roots. Clin Cancer Res. 2011;17(19):6125\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2743.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3244_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.stem.2007.08.001","volume":"1","author":"M Todaro","year":"2007","unstructured":"Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1(4):389\u2013402. https:\/\/doi.org\/10.1016\/j.stem.2007.08.001.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"3244_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.stem.2008.07.012","volume":"3","author":"CF Kim","year":"2008","unstructured":"Kim CF, Dirks PB. Cancer and stem cell biology: how tightly intertwined? Cell Stem Cell. 2008;3(2):147\u201350. https:\/\/doi.org\/10.1016\/j.stem.2008.07.012.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"3244_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jcb.24317","volume":"114","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Abubaker K, Findlay J, Quinn M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem. 2013;114(1):21\u201334. https:\/\/doi.org\/10.1002\/jcb.24317.","journal-title":"J Cell Biochem"},{"issue":"11","key":"3244_CR28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/S1470-2045(09)70238-4","volume":"10","author":"RA Soo","year":"2009","unstructured":"Soo RA, Anderson BO, Cho BC, Yang CH, Liao M, Lim WT, Goldstraw P, Mok TS, Asian Oncology Summit. First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1102\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(09)70238-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3244_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"key":"3244_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69. https:\/\/doi.org\/10.1186\/1748-5908-5-69.","journal-title":"Implement Sci"},{"issue":"4","key":"3244_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41571-019-0293-2","volume":"17","author":"JA Clara","year":"2020","unstructured":"Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells\u2014a clinical update. Nat Rev Clin Oncol. 2020;17(4):204\u201332. https:\/\/doi.org\/10.1038\/s41571-019-0293-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"43","key":"3244_CR32","doi-asserted-by":"publisher","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","volume":"109","author":"SM McAuliffe","year":"2012","unstructured":"McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J Jr, Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, Berkowitz RS, Aster JC, Matulonis UA, Dinulescu DM. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA. 2012;109(43):E2939\u201348. https:\/\/doi.org\/10.1073\/pnas.1206400109.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"3244_CR33","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-08-0001","volume":"68","author":"JH Choi","year":"2008","unstructured":"Choi JH, Park JT, Davidson B, Morin PJ, Shih IM, Wang TL. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res. 2008;68(14):5716\u201323. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0001.","journal-title":"Cancer Res"},{"issue":"5415","key":"3244_CR34","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.284.5415.770","volume":"284","author":"S Artavanis-Tsakonas","year":"1999","unstructured":"Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284(5415):770\u20136. https:\/\/doi.org\/10.1126\/science.284.5415.770.","journal-title":"Science"},{"issue":"2","key":"3244_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11670-011-0140-1","volume":"23","author":"LY Jiang","year":"2011","unstructured":"Jiang LY, Zhang XL, Du P, Zheng JH. \u03b3-Secretase inhibitor, DAPT inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro. Chin J Cancer Res. 2011;23(2):140\u20136. https:\/\/doi.org\/10.1007\/s11670-011-0140-1.","journal-title":"Chin J Cancer Res"},{"issue":"9","key":"3244_CR36","doi-asserted-by":"publisher","first-page":"e107596","DOI":"10.1371\/journal.pone.0107596","volume":"9","author":"SS Kakar","year":"2014","unstructured":"Kakar SS, Ratajczak MZ, Powell KS, Moghadamfalahi M, Miller DM, Batra SK, Singh SK. Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells. PLoS ONE. 2014;9(9):e107596. https:\/\/doi.org\/10.1371\/journal.pone.0107596.","journal-title":"PLoS ONE"},{"issue":"42","key":"3244_CR37","doi-asserted-by":"publisher","first-page":"68229","DOI":"10.18632\/oncotarget.11920","volume":"7","author":"HG Kang","year":"2016","unstructured":"Kang HG, Kim DH, Kim SJ, Cho Y, Jung J, Jang W, Chun KH. Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget. 2016;7(42):68229\u201341. https:\/\/doi.org\/10.18632\/oncotarget.11920.","journal-title":"Oncotarget"},{"issue":"1","key":"3244_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s13046-019-1360-3","volume":"38","author":"SS Islam","year":"2019","unstructured":"Islam SS, Aboussekhra A. Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway. J Exp Clin Cancer Res. 2019;38(1):382. https:\/\/doi.org\/10.1186\/s13046-019-1360-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"3244_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","volume":"127","author":"H Clevers","year":"2006","unstructured":"Clevers H. Wnt\/beta-catenin signaling in development and disease. Cell. 2006;127(3):469\u201380. https:\/\/doi.org\/10.1016\/j.cell.2006.10.018.","journal-title":"Cell"},{"issue":"1","key":"3244_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald BT, Tamai K, He X. Wnt\/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9\u201326. https:\/\/doi.org\/10.1016\/j.devcel.2009.06.016.","journal-title":"Dev Cell"},{"issue":"5973","key":"3244_CR41","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","volume":"327","author":"Y Wang","year":"2010","unstructured":"Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650\u20133. https:\/\/doi.org\/10.1126\/science.1186624.","journal-title":"Science"},{"issue":"27","key":"3244_CR42","doi-asserted-by":"publisher","first-page":"23720","DOI":"10.18632\/oncotarget.4690","volume":"6","author":"AB Nagaraj","year":"2015","unstructured":"Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, DiFeo A. Critical role of Wnt\/\u03b2-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget. 2015;6(27):23720\u201334. https:\/\/doi.org\/10.18632\/oncotarget.4690.","journal-title":"Oncotarget"},{"key":"3244_CR43","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/onc.2012.290","volume":"32","author":"WK Chau","year":"2013","unstructured":"Chau WK, Ip CK, Mak ASC, et al. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt\/\u03b2-catenin-ATP-binding cassette G2 signaling. Oncogene. 2013;32:2767\u201381.","journal-title":"Oncogene"},{"key":"3244_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jff.2018.09.021","volume":"50","author":"H Pan","year":"2018","unstructured":"Pan H, Kim E, Rankin GO, Rojanasakul Y, Tu Y, Chen YC. Theaflavin-3, 3\u2032-digallate inhibits ovarian cancer stem cells by suppressing Wnt\/\u03b2-catenin signaling pathway. J Funct Foods. 2018;50:1\u20137. https:\/\/doi.org\/10.1016\/j.jff.2018.09.021.","journal-title":"J Funct Foods"},{"issue":"16","key":"3244_CR45","doi-asserted-by":"publisher","first-page":"25897","DOI":"10.18632\/oncotarget.13071","volume":"8","author":"S Deng","year":"2017","unstructured":"Deng S, Wong CKC, Lai HC, Wong AST. Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt\/\u03b2-catenin signaling and epithelial-to-mesenchymal transition. Oncotarget. 2017;8(16):25897\u2013914. https:\/\/doi.org\/10.18632\/oncotarget.13071.","journal-title":"Oncotarget"},{"issue":"18","key":"3244_CR46","doi-asserted-by":"publisher","first-page":"14481","DOI":"10.18632\/oncotarget.24520","volume":"9","author":"AK Srivastava","year":"2018","unstructured":"Srivastava AK, Rizvi A, Cui T, Han C, Banerjee A, Naseem I, Zheng Y, Wani AA, Wang QE. Depleting ovarian cancer stem cells with calcitriol. Oncotarget. 2018;9(18):14481\u201391. https:\/\/doi.org\/10.18632\/oncotarget.24520.","journal-title":"Oncotarget"},{"issue":"Suppl 3","key":"3244_CR47","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.3816\/CBC.2010.s.013","volume":"10","author":"PF McAuliffe","year":"2010","unstructured":"McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the role of PI3K\/Akt\/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer. 2010;10(Suppl 3):S59-65. https:\/\/doi.org\/10.3816\/CBC.2010.s.013.","journal-title":"Clin Breast Cancer"},{"key":"3244_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019;59:147\u201360. https:\/\/doi.org\/10.1016\/j.semcancer.2019.05.012.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"3244_CR49","doi-asserted-by":"publisher","first-page":"C281","DOI":"10.1152\/ajpcell.00422.2003","volume":"287","author":"N Gao","year":"2004","unstructured":"Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K\/AKT\/mTOR\/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287(2):C281\u201391. https:\/\/doi.org\/10.1152\/ajpcell.00422.2003.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"3244_CR50","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1186\/s12885-019-5824-9","volume":"19","author":"J Deng","year":"2019","unstructured":"Deng J, Bai X, Feng X, Ni J, Beretov J, Graham P, Li Y. Inhibition of PI3K\/Akt\/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer. 2019;19(1):618. https:\/\/doi.org\/10.1186\/s12885-019-5824-9.","journal-title":"BMC Cancer"},{"issue":"18","key":"3244_CR51","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.4161\/cbt.8.18.9285","volume":"8","author":"JM Green","year":"2009","unstructured":"Green JM, Alvero AB, Kohen F, Mor G. 7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: a novel compound capable of inducing cell death in epithelial ovarian cancer stem cells. Cancer Biol Ther. 2009;8(18):1747\u201353. https:\/\/doi.org\/10.4161\/cbt.8.18.9285.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"3244_CR52","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3892\/or.2017.5709","volume":"38","author":"Y Ning","year":"2017","unstructured":"Ning Y, Xu M, Cao X, Chen X, Luo X. Inactivation of AKT, ERK and NF-\u03baB by genistein derivative, 7-difluoromethoxyl-5,4\u2032-di-n-octylygenistein, reduces ovarian carcinoma oncogenicity. Oncol Rep. 2017;38(2):949\u201358. https:\/\/doi.org\/10.3892\/or.2017.5709.","journal-title":"Oncol Rep"},{"key":"3244_CR53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-019-0780-7","volume":"19","author":"WY Wang","year":"2019","unstructured":"Wang WY, Cao YX, Zhou X, Wei B, Zhan L, Sun SY. Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway. Cancer Cell Int. 2019;19:86. https:\/\/doi.org\/10.1186\/s12935-019-0780-7.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"3244_CR54","doi-asserted-by":"publisher","first-page":"a000034","DOI":"10.1101\/cshperspect.a000034","volume":"1","author":"A Oeckinghaus","year":"2009","unstructured":"Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):a000034. https:\/\/doi.org\/10.1101\/cshperspect.a000034.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"8","key":"3244_CR55","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cancers11081182","volume":"11","author":"BS Harrington","year":"2019","unstructured":"Harrington BS, Annunziata CM. NF-\u03baB signaling in ovarian cancer. Cancers (Basel). 2019;11(8):1182. https:\/\/doi.org\/10.3390\/cancers11081182.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3244_CR56","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.arcmed.2017.08.001","volume":"48","author":"C Gonzalez-Torres","year":"2017","unstructured":"Gonzalez-Torres C, Gaytan-Cervantes J, Vazquez-Santillan K, Mandujano-Tinoco EA, Ceballos-Cancino G, Garcia-Venzor A, Zampedri C, Sanchez-Maldonado P, Mojica-Espinosa R, Jimenez-Hernandez LE, Maldonado V. NF-\u03baB participates in the stem cell phenotype of ovarian cancer cells. Arch Med Res. 2017;48(4):343\u201351. https:\/\/doi.org\/10.1016\/j.arcmed.2017.08.001.","journal-title":"Arch Med Res"},{"issue":"4","key":"3244_CR57","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1600-0897.2010.00914.x","volume":"65","author":"AL Leizer","year":"2011","unstructured":"Leizer AL, Alvero AB, Fu HH, Holmberg JC, Cheng YC, Silasi DA, Rutherford T, Mor G. Regulation of inflammation by the NF-\u03baB pathway in ovarian cancer stem cells. Am J Reprod Immunol. 2011;65(4):438\u201347. https:\/\/doi.org\/10.1111\/j.1600-0897.2010.00914.x.","journal-title":"Am J Reprod Immunol"},{"key":"3244_CR58","doi-asserted-by":"publisher","first-page":"748403","DOI":"10.3389\/fonc.2022.748403","volume":"12","author":"YX Jiang","year":"2022","unstructured":"Jiang YX, Siu MKY, Wang JJ, Leung THY, Chan DW, Cheung ANY, Ngan HYS, Chan KKL. PFKFB3 regulates chemoresistance, metastasis and stemness via IAP proteins and the NF-\u03baB signaling pathway in ovarian cancer. Front Oncol. 2022;12:748403. https:\/\/doi.org\/10.3389\/fonc.2022.748403.","journal-title":"Front Oncol"},{"issue":"4","key":"3244_CR59","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246\u201357. https:\/\/doi.org\/10.1038\/nrc3458.","journal-title":"Nat Rev Cancer"},{"key":"3244_CR60","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.semcancer.2021.06.001","volume":"85","author":"Y Song","year":"2022","unstructured":"Song Y, Pan S, Li K, Chen X, Wang ZP, Zhu X. Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers. Semin Cancer Biol. 2022;85:219\u201333. https:\/\/doi.org\/10.1016\/j.semcancer.2021.06.001.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"3244_CR61","doi-asserted-by":"publisher","first-page":"e109575","DOI":"10.1371\/journal.pone.0109575","volume":"9","author":"Y Xia","year":"2014","unstructured":"Xia Y, Zhang YL, Yu C, Chang T, Fan HY. YAP\/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS ONE. 2014;9(11):e109575. https:\/\/doi.org\/10.1371\/journal.pone.0109575.","journal-title":"PLoS ONE"},{"key":"3244_CR62","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.2147\/OTT.S109979","volume":"9","author":"J Feng","year":"2016","unstructured":"Feng J, Gou J, Jia J, Yi T, Cui T, Li Z. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther. 2016;9:5371\u201381. https:\/\/doi.org\/10.2147\/OTT.S109979.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"3244_CR63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/01443615.2017.1336753","volume":"38","author":"A Bartakova","year":"2018","unstructured":"Bartakova A, Michalova K, Presl J, Vlasak P, Kostun J, Bouda J. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma. J Obstet Gynaecol. 2018;38(1):110\u20134. https:\/\/doi.org\/10.1080\/01443615.2017.1336753.","journal-title":"J Obstet Gynaecol"},{"issue":"1","key":"3244_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64. https:\/\/doi.org\/10.1186\/s13045-018-0605-5.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3244_CR65","doi-asserted-by":"publisher","first-page":"273","DOI":"10.15537\/smj.2015.3.9622","volume":"36","author":"NS Basakran","year":"2015","unstructured":"Basakran NS. CD44 as a potential diagnostic tumor marker. Saudi Med J. 2015;36(3):273\u20139. https:\/\/doi.org\/10.15537\/smj.2015.3.9622.","journal-title":"Saudi Med J"},{"key":"3244_CR66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fcell.2017.00018","volume":"5","author":"LT Senbanjo","year":"2017","unstructured":"Senbanjo LT, Chellaiah MA. CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 2017;5:18. https:\/\/doi.org\/10.3389\/fcell.2017.00018.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"3244_CR67","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1440-1827.2006.01925.x","volume":"56","author":"EY Cho","year":"2006","unstructured":"Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int. 2006;56(2):62\u201370. https:\/\/doi.org\/10.1111\/j.1440-1827.2006.01925.x.","journal-title":"Pathol Int"},{"issue":"4","key":"3244_CR68","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.3390\/biom5043051","volume":"5","author":"JD Sacks","year":"2015","unstructured":"Sacks JD, Barbolina MV. Expression and function of CD44 in epithelial ovarian carcinoma. Biomolecules. 2015;5(4):3051\u201366. https:\/\/doi.org\/10.3390\/biom5043051.","journal-title":"Biomolecules"},{"issue":"3","key":"3244_CR69","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/sj.bjc.6605185","volume":"101","author":"H Chen","year":"2009","unstructured":"Chen H, Hao J, Wang L, Li Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer. 2009;101(3):432\u201340. https:\/\/doi.org\/10.1038\/sj.bjc.6605185.","journal-title":"Br J Cancer"},{"issue":"1","key":"3244_CR70","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4161\/cc.8.1.7533","volume":"8","author":"AB Alvero","year":"2009","unstructured":"Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8(1):158\u201366. https:\/\/doi.org\/10.4161\/cc.8.1.7533.","journal-title":"Cell Cycle"},{"issue":"24","key":"3244_CR71","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1002\/cncr.26215","volume":"117","author":"F Casagrande","year":"2011","unstructured":"Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer. 2011;117(24):5519\u201328. https:\/\/doi.org\/10.1002\/cncr.26215.","journal-title":"Cancer"},{"issue":"11","key":"3244_CR72","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/j.1742-4658.2012.08589.x","volume":"279","author":"W Cheng","year":"2012","unstructured":"Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279(11):2047\u201359. https:\/\/doi.org\/10.1111\/j.1742-4658.2012.08589.x.","journal-title":"FEBS J"},{"issue":"2","key":"3244_CR73","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.canlet.2009.01.013","volume":"278","author":"N Ta\u00efeb","year":"2009","unstructured":"Ta\u00efeb N, Maresca M, Guo XJ, Garmy N, Fantini J, Yahi N. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett. 2009;278(2):164\u201373. https:\/\/doi.org\/10.1016\/j.canlet.2009.01.013.","journal-title":"Cancer Lett"},{"issue":"1","key":"3244_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40169-018-0198-1","volume":"7","author":"PM Glumac","year":"2018","unstructured":"Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med. 2018;7(1):18. https:\/\/doi.org\/10.1186\/s40169-018-0198-1.","journal-title":"Clin Transl Med"},{"issue":"23","key":"3244_CR75","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","volume":"65","author":"AT Collins","year":"2005","unstructured":"Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2018.","journal-title":"Cancer Res"},{"issue":"1","key":"3244_CR76","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ijc.25967","volume":"130","author":"I Kryczek","year":"2012","unstructured":"Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer. 2012;130(1):29\u201339. https:\/\/doi.org\/10.1002\/ijc.25967.","journal-title":"Int J Cancer"},{"issue":"3","key":"3244_CR77","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/path.4086","volume":"229","author":"P Grosse-Gehling","year":"2013","unstructured":"Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, Kunz-Schughart LA. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol. 2013;229(3):355\u201378. https:\/\/doi.org\/10.1002\/path.4086.","journal-title":"J Pathol"},{"issue":"3","key":"3244_CR78","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ygyno.2013.05.027","volume":"130","author":"AP Skubitz","year":"2013","unstructured":"Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol. 2013;130(3):579\u201387. https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.027.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3244_CR79","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3892\/or.2016.5263","volume":"37","author":"Q Long","year":"2017","unstructured":"Long Q, Yang R, Lu W, Zhu W, Zhou J, Zheng C, Zhou D, Yu L, Wu J. Adenovirus-mediated truncated Bid overexpression induced by the Cre\/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells. Oncol Rep. 2017;37(1):155\u201362. https:\/\/doi.org\/10.3892\/or.2016.5263.","journal-title":"Oncol Rep"},{"issue":"2","key":"3244_CR80","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/onc.2013.537","volume":"34","author":"T Xiang","year":"2015","unstructured":"Xiang T, Long H, He L, Han X, Lin K, Liang Z, Zhuo W, Xie R, Zhu B. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene. 2015;34(2):165\u201376. https:\/\/doi.org\/10.1038\/onc.2013.537.","journal-title":"Oncogene"},{"issue":"46","key":"3244_CR81","doi-asserted-by":"publisher","first-page":"76006","DOI":"10.18632\/oncotarget.12579","volume":"7","author":"D Wang","year":"2016","unstructured":"Wang D, Xiang T, Zhao Z, Lin K, Yin P, Jiang L, Liang Z, Zhu B. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells. Oncotarget. 2016;7(46):76006\u201320. https:\/\/doi.org\/10.18632\/oncotarget.12579.","journal-title":"Oncotarget"},{"issue":"4\u20135","key":"3244_CR82","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3109\/10409239209082565","volume":"27","author":"R Lindahl","year":"1992","unstructured":"Lindahl R. Aldehyde dehydrogenases and their role in carcinogenesis. Crit Rev Biochem Mol Biol. 1992;27(4\u20135):283\u2013335. https:\/\/doi.org\/10.3109\/10409239209082565.","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"1","key":"3244_CR83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12905-018-0686-x","volume":"18","author":"Y Xia","year":"2018","unstructured":"Xia Y, Wei X, Gong H, Ni Y. Aldehyde dehydrogenase serves as a biomarker for worse survival profiles in ovarian cancer patients: an updated meta-analysis. BMC Womens Health. 2018;18(1):199. https:\/\/doi.org\/10.1186\/s12905-018-0686-x.","journal-title":"BMC Womens Health"},{"issue":"20","key":"3244_CR84","doi-asserted-by":"publisher","first-page":"8208","DOI":"10.1158\/0008-5472.CAN-09-1132","volume":"69","author":"JE Carpentino","year":"2009","unstructured":"Carpentino JE, Hynes MJ, Appelman HD, Zheng T, Steindler DA, Scott EW, Huang EH. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 2009;69(20):8208\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1132.","journal-title":"Cancer Res"},{"issue":"4","key":"3244_CR85","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bbrc.2010.04.170","volume":"396","author":"S Sun","year":"2010","unstructured":"Sun S, Wang Z. ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis. Biochem Biophys Res Commun. 2010;396(4):843\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2010.04.170.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"3244_CR86","doi-asserted-by":"publisher","first-page":"e10277","DOI":"10.1371\/journal.pone.0010277","volume":"5","author":"S Deng","year":"2010","unstructured":"Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, B\u00fctzow R, Coukos G, Zhang L. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE. 2010;5(4):e10277. https:\/\/doi.org\/10.1371\/journal.pone.0010277.","journal-title":"PLoS ONE"},{"issue":"8","key":"3244_CR87","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1172\/JCI45273","volume":"121","author":"K McLean","year":"2011","unstructured":"McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR, Buckanovich RJ. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Investig. 2011;121(8):3206\u201319. https:\/\/doi.org\/10.1172\/JCI45273.","journal-title":"J Clin Investig"},{"key":"3244_CR88","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.biocel.2016.07.017","volume":"78","author":"R Januchowski","year":"2016","unstructured":"Januchowski R, Wojtowicz K, Sterzy\u017fska K, Sosi\u017fska P, Andrzejewska M, Zawierucha P, Nowicki M, Zabel M. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines. Int J Biochem Cell Biol. 2016;78:248\u201359. https:\/\/doi.org\/10.1016\/j.biocel.2016.07.017.","journal-title":"Int J Biochem Cell Biol"},{"issue":"8","key":"3244_CR89","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.humpath.2012.12.016","volume":"44","author":"CA Liebscher","year":"2013","unstructured":"Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, Sehouli J, Braicu EI, Dietel M, Darb-Esfahani S. Aldehyde dehydrogenase 1\/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Hum Pathol. 2013;44(8):1465\u201371. https:\/\/doi.org\/10.1016\/j.humpath.2012.12.016.","journal-title":"Hum Pathol"},{"issue":"6","key":"3244_CR90","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/modpathol.2009.35","volume":"22","author":"B Chang","year":"2009","unstructured":"Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol. 2009;22(6):817\u201323. https:\/\/doi.org\/10.1038\/modpathol.2009.35.","journal-title":"Mod Pathol"},{"issue":"9","key":"3244_CR91","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41419-018-0903-4","volume":"9","author":"D Kim","year":"2018","unstructured":"Kim D, Choi BH, Ryoo IG, Kwak MK. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH\/NRF2 signaling. Cell Death Dis. 2018;9(9):896. https:\/\/doi.org\/10.1038\/s41419-018-0903-4.","journal-title":"Cell Death Dis"},{"issue":"4","key":"3244_CR92","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/carcin\/bgv018","volume":"36","author":"MJ Young","year":"2015","unstructured":"Young MJ, Wu YH, Chiu WT, Weng TY, Huang YF, Chou CY. All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells. Carcinogenesis. 2015;36(4):498\u2013507. https:\/\/doi.org\/10.1093\/carcin\/bgv018.","journal-title":"Carcinogenesis"},{"issue":"5","key":"3244_CR93","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41419-018-0585-y","volume":"9","author":"T Cui","year":"2018","unstructured":"Cui T, Srivastava AK, Han C, Wu D, Wani N, Liu L, Gao Z, Qu M, Zou N, Zhang X, Yi P, Yu J, Bell EH, Yang SM, Maloney DJ, Zheng Y, Wani AA, Wang QE. DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1. Cell Death Dis. 2018;9(5):561. https:\/\/doi.org\/10.1038\/s41419-018-0585-y.","journal-title":"Cell Death Dis"},{"key":"3244_CR94","doi-asserted-by":"publisher","unstructured":"Kakar SS, Parte S, Carter K, Joshua IG, Worth C, Rameshwar P, Ratajczak MZ. Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget. 2017;8(43):74494\u2013505. https:\/\/doi.org\/10.18632\/oncotarget.20170. Erratum in: Oncotarget. 2020; 11(32):3103\u20134.","DOI":"10.18632\/oncotarget.20170"},{"issue":"12","key":"3244_CR95","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1158\/1535-7163.MCT-10-0563","volume":"9","author":"CN Landen Jr","year":"2010","unstructured":"Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010;9(12):3186\u201399. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0563.","journal-title":"Mol Cancer Ther"},{"issue":"50","key":"3244_CR96","doi-asserted-by":"publisher","first-page":"E6882","DOI":"10.1073\/pnas.1507899112","volume":"112","author":"YJ Choi","year":"2015","unstructured":"Choi YJ, Ingram PN, Yang K, Coffman L, Iyengar M, Bai S, Thomas DG, Yoon E, Buckanovich RJ. Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2. Proc Natl Acad Sci USA. 2015;112(50):E6882\u20138. https:\/\/doi.org\/10.1073\/pnas.1507899112.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"3244_CR97","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s42255-019-0146-4","volume":"1","author":"EA Day","year":"2019","unstructured":"Day EA, Ford RJ, Smith BK, Mohammadi-Shemirani P, Morrow MR, Gutgesell RM, Lu R, Raphenya AR, Kabiri M, McArthur AG, McInnes N, Hess S, Par\u00e9 G, Gerstein HC, Steinberg GR. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab. 2019;1(12):1202\u20138. https:\/\/doi.org\/10.1038\/s42255-019-0146-4.","journal-title":"Nat Metab"},{"issue":"1","key":"3244_CR98","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cmet.2020.04.015","volume":"32","author":"LP Bharath","year":"2020","unstructured":"Bharath LP, Agrawal M, McCambridge G, Nicholas DA, Hasturk H, Liu J, Jiang K, Liu R, Guo Z, Deeney J, Apovian CM, Snyder-Cappione J, Hawk GS, Fleeman RM, Pihl RMF, Thompson K, Belkina AC, Cui L, Proctor EA, Kern PA, Nikolajczyk BS. Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation. Cell Metab. 2020;32(1):44\u201355. https:\/\/doi.org\/10.1016\/j.cmet.2020.04.015.","journal-title":"Cell Metab"},{"issue":"11","key":"3244_CR99","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.2337\/dc20-0892","volume":"43","author":"K Samaras","year":"2020","unstructured":"Samaras K, Makkar S, Crawford JD, Kochan NA, Wen W, Draper B, Trollor JN, Brodaty H, Sachdev PS. Metformin Use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney memory and ageing study. Diabetes Care. 2020;43(11):2691\u2013701. https:\/\/doi.org\/10.2337\/dc20-0892.","journal-title":"Diabetes Care"},{"issue":"4","key":"3244_CR100","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1470-2045(16)00006-1","volume":"17","author":"AT Chan","year":"2016","unstructured":"Chan AT. Metformin for cancer prevention: a reason for optimism. Lancet Oncol. 2016;17(4):407\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(16)00006-1.","journal-title":"Lancet Oncol"},{"key":"3244_CR101","doi-asserted-by":"publisher","first-page":"e02242","DOI":"10.7554\/eLife.02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS, Chandel NS. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242. https:\/\/doi.org\/10.7554\/eLife.02242.","journal-title":"Elife"},{"issue":"8","key":"3244_CR102","doi-asserted-by":"publisher","first-page":"e71583","DOI":"10.1371\/journal.pone.0071583","volume":"8","author":"M Franciosi","year":"2013","unstructured":"Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE. 2013;8(8):e71583. https:\/\/doi.org\/10.1371\/journal.pone.0071583.","journal-title":"PLoS ONE"},{"issue":"2","key":"3244_CR103","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ygyno.2012.07.115","volume":"127","author":"JJ Shank","year":"2012","unstructured":"Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK, Buckanovich RJ. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol. 2012;127(2):390\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2012.07.115.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3244_CR104","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","volume":"11","author":"C Calabrese","year":"2007","unstructured":"Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69\u201382. https:\/\/doi.org\/10.1016\/j.ccr.2006.11.020.","journal-title":"Cancer Cell"},{"issue":"14","key":"3244_CR105","doi-asserted-by":"publisher","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-06-4447","volume":"67","author":"M Buzzai","year":"2007","unstructured":"Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67(14):6745\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4447.","journal-title":"Cancer Res"},{"key":"3244_CR106","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13287-015-0249-0","volume":"6","author":"R Zhang","year":"2015","unstructured":"Zhang R, Zhang P, Wang H, Hou D, Li W, Xiao G, Li C. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells. Stem Cell Res Ther. 2015;6:262. https:\/\/doi.org\/10.1186\/s13287-015-0249-0.","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"3244_CR107","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.17219\/acem\/73999","volume":"27","author":"A Markowska","year":"2018","unstructured":"Markowska A, Sajdak S, Huczy\u0144ski A, Rehlis S, Markowska J. Ovarian cancer stem cells: a target for oncological therapy. Adv Clin Exp Med. 2018;27(7):1017\u201320. https:\/\/doi.org\/10.17219\/acem\/73999.","journal-title":"Adv Clin Exp Med"},{"issue":"4","key":"3244_CR108","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.bbrc.2010.03.138","volume":"394","author":"D Fuchs","year":"2010","unstructured":"Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010;394(4):1098\u2013104. https:\/\/doi.org\/10.1016\/j.bbrc.2010.03.138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"3244_CR109","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1245\/s10434-011-1561-2","volume":"18","author":"TT Dong","year":"2011","unstructured":"Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH. Salinomycin selectively targets \u2018CD133+\u2019 cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol. 2011;18(6):1797\u2013804. https:\/\/doi.org\/10.1245\/s10434-011-1561-2.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"3244_CR110","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2174\/157340611794859307","volume":"7","author":"Y Wang","year":"2011","unstructured":"Wang Y. Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med Chem. 2011;7(2):106\u201311. https:\/\/doi.org\/10.2174\/157340611794859307.","journal-title":"Med Chem"},{"issue":"7","key":"3244_CR111","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.biopha.2011.06.006","volume":"65","author":"QM Zhi","year":"2011","unstructured":"Zhi QM, Chen XH, Ji J, Zhang JN, Li JF, Cai Q, Liu BY, Gu QL, Zhu ZG, Yu YY. Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed Pharmacother. 2011;65(7):509\u201315. https:\/\/doi.org\/10.1016\/j.biopha.2011.06.006.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"3244_CR112","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1002\/ijc.27595","volume":"131","author":"PS Oak","year":"2012","unstructured":"Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P, Roidl A. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer. 2012;131(12):2808\u201319. https:\/\/doi.org\/10.1002\/ijc.27595.","journal-title":"Int J Cancer"},{"issue":"2","key":"3244_CR113","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.biomaterials.2011.09.072","volume":"33","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zhang H, Wang X, Wang J, Zhang X, Zhang Q. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials. 2012;33(2):679\u201391. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.09.072.","journal-title":"Biomaterials"},{"issue":"4","key":"3244_CR114","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/cas.13186","volume":"108","author":"Y Wen","year":"2017","unstructured":"Wen Y, Hou Y, Huang Z, Cai J, Wang Z. SOX2 is required to maintain cancer stem cells in ovarian cancer. Cancer Sci. 2017;108(4):719\u201331. https:\/\/doi.org\/10.1111\/cas.13186.","journal-title":"Cancer Sci"},{"issue":"2","key":"3244_CR115","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.3802\/jgo.2017.28.e14","volume":"28","author":"HG Lee","year":"2017","unstructured":"Lee HG, Shin SJ, Chung HW, Kwon SH, Cha SD, Lee JE, Cho CH. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell. J Gynecol Oncol. 2017;28(2):e14. https:\/\/doi.org\/10.3802\/jgo.2017.28.e14.","journal-title":"J Gynecol Oncol."},{"issue":"5","key":"3244_CR116","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.3892\/ol.2018.8140","volume":"15","author":"Y Mi","year":"2018","unstructured":"Mi Y, Huang Y, Deng J. The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles. Oncol Lett. 2018;15(5):6611\u201321. https:\/\/doi.org\/10.3892\/ol.2018.8140.","journal-title":"Oncol Lett"},{"issue":"7","key":"3244_CR117","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm1155","volume":"4","author":"MJ Berridge","year":"2003","unstructured":"Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4(7):517\u201329. https:\/\/doi.org\/10.1038\/nrm1155.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3244_CR118","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4419-6066-5_10","volume":"674","author":"A Becchetti","year":"2010","unstructured":"Becchetti A, Arcangeli A. Integrins and ion channels in cell migration: implications for neuronal development, wound healing and metastatic spread. Adv Exp Med Biol. 2010;674:107\u201323. https:\/\/doi.org\/10.1007\/978-1-4419-6066-5_10.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"3244_CR119","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nrn2093","volume":"8","author":"RD Burgoyne","year":"2007","unstructured":"Burgoyne RD. Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signalling. Nat Rev Neurosci. 2007;8(3):182\u201393. https:\/\/doi.org\/10.1038\/nrn2093.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"3244_CR120","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/15748928130102","volume":"8","author":"T Capiod","year":"2013","unstructured":"Capiod T. The need for calcium channels in cell proliferation. Recent Pat Anticancer Drug Discov. 2013;8(1):4\u201317. https:\/\/doi.org\/10.2174\/15748928130102.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"12","key":"3244_CR121","doi-asserted-by":"publisher","first-page":"e115698","DOI":"10.1371\/journal.pone.0115698","volume":"9","author":"S Wee","year":"2014","unstructured":"Wee S, Niklasson M, Marinescu VD, Segerman A, Schmidt L, Hermansson A, Dirks P, Forsberg-Nilsson K, Westermark B, Uhrbom L, Linnarsson S, Nelander S, And\u00e4ng M. Selective calcium sensitivity in immature glioma cancer stem cells. PLoS ONE. 2014;9(12):e115698. https:\/\/doi.org\/10.1371\/journal.pone.0115698.","journal-title":"PLoS ONE"},{"issue":"7","key":"3244_CR122","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1158\/0008-5472.CAN-16-2274","volume":"77","author":"M Niklasson","year":"2017","unstructured":"Niklasson M, Maddalo G, Sramkova Z, Mutlu E, Wee S, Sekyrova P, Schmidt L, Fritz N, Dehnisch I, Kyriatzis G, Krafcikova M, Carson BB, Feenstra JM, Marinescu VD, Segerman A, Haraldsson M, Gustavsson AL, Hammarstr\u00f6m LG, Jenmalm Jensen A, Uhrbom L, Altelaar AF, Linnarsson S, Uhl\u00e9n P, Trantirek L, Vincent CT, Nelander S, Enger P\u00d8, And\u00e4ng M. Membrane-depolarizing channel blockers induce selective glioma cell death by impairing nutrient transport and unfolded protein\/amino acid responses. Cancer Res. 2017;77(7):1741\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2274.","journal-title":"Cancer Res"},{"issue":"7","key":"3244_CR123","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3390\/ijms21072327","volume":"21","author":"H Lee","year":"2020","unstructured":"Lee H, Kim JW, Kim DK, Choi DK, Lee S, Yu JH, Kwon OB, Lee J, Lee DS, Kim JH, Min SH. Calcium channels as novel therapeutic targets for ovarian cancer stem cells. Int J Mol Sci. 2020;21(7):2327. https:\/\/doi.org\/10.3390\/ijms21072327.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"3244_CR124","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.3390\/ijms21197379","volume":"21","author":"H Lee","year":"2020","unstructured":"Lee H, Kim JW, Lee DS, Min SH. Combined poziotinib with manidipine treatment suppresses ovarian cancer stem-cell proliferation and stemness. Int J Mol Sci. 2020;21(19):7379. https:\/\/doi.org\/10.3390\/ijms21197379.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3244_CR125","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3390\/ijms18102171","volume":"18","author":"R Cornelison","year":"2017","unstructured":"Cornelison R, Llaneza DC, Landen CN. Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: a mini-review. Int J Mol Sci. 2017;18(10):2171. https:\/\/doi.org\/10.3390\/ijms18102171.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"3244_CR126","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1016\/j.febslet.2014.02.011","volume":"588","author":"R Aloni-Grinstein","year":"2014","unstructured":"Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V. p53: the barrier to cancer stem cell formation. FEBS Lett. 2014;588(16):2580\u20139. https:\/\/doi.org\/10.1016\/j.febslet.2014.02.011.","journal-title":"FEBS Lett"},{"issue":"25","key":"3244_CR127","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1038\/onc.2016.518","volume":"36","author":"M Escoll","year":"2017","unstructured":"Escoll M, Gargini R, Cuadrado A, Anton IM, Wandosell F. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP\/TAZ. Oncogene. 2017;36(25):3515\u201327. https:\/\/doi.org\/10.1038\/onc.2016.518.","journal-title":"Oncogene"},{"issue":"12","key":"3244_CR128","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41388-017-0060-8","volume":"37","author":"H Solomon","year":"2018","unstructured":"Solomon H, Dinowitz N, Pateras IS, Cooks T, Shetzer Y, Molchadsky A, Charni M, Rabani S, Koifman G, Tarcic O, Porat Z, Kogan-Sakin I, Goldfinger N, Oren M, Harris CC, Gorgoulis VG, Rotter V. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. Oncogene. 2018;37(12):1669\u201384. https:\/\/doi.org\/10.1038\/s41388-017-0060-8.","journal-title":"Oncogene"},{"issue":"34","key":"3244_CR129","doi-asserted-by":"publisher","first-page":"55624","DOI":"10.18632\/oncotarget.10954","volume":"7","author":"EJ Seo","year":"2016","unstructured":"Seo EJ, Kim DK, Jang IH, Choi EJ, Shin SH, Lee SI, Kwon SM, Kim KH, Suh DS, Kim JH. Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer. Oncotarget. 2016;7(34):55624\u201338. https:\/\/doi.org\/10.18632\/oncotarget.10954.","journal-title":"Oncotarget"},{"issue":"1","key":"3244_CR130","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12967-019-2005-1","volume":"17","author":"W Zhu","year":"2019","unstructured":"Zhu W, Niu J, He M, Zhang L, Lv X, Liu F, Jiang L, Zhang J, Yu Z, Zhao L, Bi J, Yan Y, Wei Q, Huo H, Fan Y, Chen Y, Ding J, Wei M. SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway. J Transl Med. 2019;17(1):259. https:\/\/doi.org\/10.1186\/s12967-019-2005-1.","journal-title":"J Transl Med"},{"key":"3244_CR131","doi-asserted-by":"publisher","first-page":"583087","DOI":"10.3389\/fcell.2020.583087","volume":"8","author":"L Zhang","year":"2020","unstructured":"Zhang L, Ma R, Gao M, Zhao Y, Lv X, Zhu W, Han L, Su P, Fan Y, Yan Y, Zhao L, Ma H, Wei M, He M. SNORA72 activates the Notch1\/c-Myc pathway to promote stemness transformation of ovarian cancer cells. Front Cell Dev Biol. 2020;8:583087. https:\/\/doi.org\/10.3389\/fcell.2020.583087.","journal-title":"Front Cell Dev Biol."},{"issue":"18","key":"3244_CR132","doi-asserted-by":"publisher","first-page":"26806","DOI":"10.18632\/oncotarget.8645","volume":"7","author":"T Mariya","year":"2016","unstructured":"Mariya T, Hirohashi Y, Torigoe T, Tabuchi Y, Asano T, Saijo H, Kuroda T, Yasuda K, Mizuuchi M, Saito T, Sato N. Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer. Oncotarget. 2016;7(18):26806\u201322. https:\/\/doi.org\/10.18632\/oncotarget.8645.","journal-title":"Oncotarget"},{"issue":"8","key":"3244_CR133","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1158\/0008-5472.CAN-16-1115","volume":"77","author":"MW Chen","year":"2017","unstructured":"Chen MW, Yang ST, Chien MH, Hua KT, Wu CJ, Hsiao SM, Lin H, Hsiao M, Su JL, Wei LH. The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer. Cancer Res. 2017;77(8):1955\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1115.","journal-title":"Cancer Res"},{"issue":"30","key":"3244_CR134","doi-asserted-by":"publisher","first-page":"28882","DOI":"10.18632\/oncotarget.4921","volume":"6","author":"G Wu","year":"2015","unstructured":"Wu G, Liu A, Zhu J, Lei F, Wu S, Zhang X, Ye L, Cao L, He S. MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt\/\u03b2-catenin signaling pathway. Oncotarget. 2015;6(30):28882\u201394. https:\/\/doi.org\/10.18632\/oncotarget.4921.","journal-title":"Oncotarget"},{"key":"3244_CR135","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13048-015-0196-5","volume":"8","author":"D Wu","year":"2015","unstructured":"Wu D, Wang J, Cai Y, Ren M, Zhang Y, Shi F, Zhao F, He X, Pan M, Yan C, Dou J. Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine. J Ovarian Res. 2015;8:68. https:\/\/doi.org\/10.1186\/s13048-015-0196-5.","journal-title":"J Ovarian Res"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-023-03244-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T05:12:38Z","timestamp":1676351558000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-023-03244-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3244"],"URL":"https:\/\/doi.org\/10.1186\/s13287-023-03244-4","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"29 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}